Rabbit Hybridoma

and, Weimin Zhu; Yu, Guoliang

doi:10.1002/9780470485408.ch6

Cited by 13 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, due to the size of the rabbit spleen, a larger pool of hybridomas can be generated from fusion of a single immunized rabbit spleen. Second, RabMAbs generally have higher affinity than mouse monoclonal antibodies [9] . Higher binding affinity is one of the critical parameters in selection of potent and efficacious therapeutic antibodies [27] , [28] , [29] .…”

Section: Discussionmentioning

confidence: 99%

“…Recently, transgenic mice and in vitro phage display were employed to generate fully human therapeutic antibodies [4] , [5] , [6] , [7] . These antibody platforms have their own limitations; it is desirable to have access to other antibody sources to increase the overall success rate of developing more effective antibody therapies [8] , [9] . Rabbit has a robust immune system to generate antibodies with high affinity and specificity [10] , [11] , [12] , [13] , but routine generation of rabbit monoclonal antibodies (RabMAbs) only become possible recently due to the availability of a stable rabbit hybridoma fusion partner cell line 240E-W2 [14] , [15] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

Leblond²,

Ke³

et al. 2010

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Rabbit antibodies have been widely used in research and diagnostics due to their high antigen specificity and affinity. Though these properties are also highly desirable for therapeutic applications, rabbit antibodies have remained untapped for human disease therapy. To evaluate the therapeutic potential of rabbit monoclonal antibodies (RabMAbs), we generated a panel of neutralizing RabMAbs against human vascular endothelial growth factor-A (VEGF). These neutralizing RabMAbs are specific to VEGF and do not cross-react to other members of the VEGF protein family. Guided by sequence and lineage analysis of a panel of neutralizing RabMAbs, we humanized the lead candidate by substituting non-critical residues with human residues within both the frameworks and the CDR regions. We showed that the humanized RabMAb retained its parental biological properties and showed potent inhibition of the growth of H460 lung carcinoma and A673 rhabdomyosarcoma xenografts in mice. These studies provide proof of principle for the feasibility of developing humanized RabMAbs as therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

Leblond²,

Ke³

et al. 2010

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…APX005M is a humanized IgG1κ antibody generated by Apexigen using its APXiMAB™ technology consisting of a rabbit hybridoma platform and mutational lineage-guided (MLG) humanization method [30][31][32]. A point mutation was introduced in the Fc-domain at position 267 from serine to aspartic acid (S267E mutation).…”

Section: Cd40 Antibodiesmentioning

confidence: 99%

APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

Filbert

Björck

Srivastava

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

Targeting CD40 with agonist antibodies is a promising approach to cancer immunotherapy. CD40 acts as a master regulator of immunity by mobilizing multiple arms of the immune system to initiate highly effective CD8 + T-cell-mediated responses against foreign pathogens and tumors. The clinical development of CD40 agonist antibodies requires careful optimization of the antibody to maximize therapeutic efficacy while minimizing adverse effects. Both epitope specificity and isotype are critical for CD40 agonist antibody mechanism of action and potency. We developed a novel antibody, APX005M, which binds with high affinity to the CD40 ligand-binding site on CD40 and is optimized for selective interaction with Fcγ receptors to enhance agonistic potency while limiting less desirable Fc-effector functions like antibody-dependent cellular cytotoxicity of CD40-expressing immune cells. APX005M is a highly potent inducer of innate and adaptive immune effector responses and represents a promising CD40 agonist antibody for induction of an effective anti-tumor immune response with a favorable safety profile.

show abstract

“…The development of a rabbit myeloma cell line allowing the efficient fusion of rabbit B cells from immunised animals was a major improvement on the antibody market. 58,91 Because rabbit monoclonal antibodies often display high affinities 58 they could be a valuable alternative to those from mouse and rat for antibody DIP-and RIPseq studies. At present, we are not aware of rabbit monoclonals generated against modified nucleic acids.…”

Section: Comparison Of Different Antibody Formatsmentioning

confidence: 99%

Antibodies specific for nucleic acid modifications

Feederle

Schepers

2017

RNA Biology

View full text Add to dashboard Cite

Nucleotide modifications constitute marks in RNA and DNA that contribute to gene regulation, development and other cellular processes. The understanding of their intricate molecular roles has been hampered by the high number of different modifications, the lack of effective methods and tools for their detection and quantification as well as by their complex structure-function relationship. The recent development of RNA and DNA immunoprecipitation followed by high-throughput sequencing (RIP- and DIP-seq) initiated detailed transcriptome- and genome-wide studies. Both techniques depend on highly specific and sensitive antibodies to specifically enrich the targeted modified nucleotides without background or potential biases. Here, we review the challenges and developments when generating and validating antibodies targeting modified nucleotides. We discuss antibody-antigen interactions, different strategies of antigen generation and compare different binder formats suitable for state-of-the-art high resolution mapping and imaging technologies.

show abstract

Rabbit Hybridoma

Cited by 13 publications

References 27 publications

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

Antibodies specific for nucleic acid modifications

Contact Info

Product

Resources

About